Inventor · disambiguated record
R. Michael Lawrence
Also filed as: LAWRENCE R M · LAWRENCE R MICHAEL
61 granted patents·6 pending applications·1,914 citations·filing 1993–2024
99Inventor score
Top patents by PatentIndex Score
67 records- 0199US5760246AConformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and methodFiled 1996·Granted Jun 2, 1998·304 cites·10 claims
- 0299US5712279AInhibitors of microsomal triglyceride transfer protein and methodBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Jan 27, 1998·319 cites·19 claims
- 0398US5739135AInhibitors of microsomal triglyceride transfer protein and methodBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Apr 14, 1998·297 cites·38 claims
- 0498US5712396Aα-phosphonosulfonate squalene synthetase inhibitorsFiled 1994·Granted Jan 27, 1998·196 cites·26 claims
- 0598US5595872ANucleic acids encoding microsomal trigyceride transfer proteinBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jan 21, 1997·278 cites·14 claims
- 0695US6713487B2Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising sameBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Mar 30, 2004·78 cites·15 claims
- 0793US10047103B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Aug 14, 2018·11 cites·22 claims
- 0893US8791091B2Aryl dihydropyridinone and piperidinone MGAT2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Jul 29, 2014·18 cites·103 claims
- 0993US5447922Aα-phosphonosulfinic squalene synthetase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Sep 5, 1995·64 cites·22 claims
- 1092US10822343B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 3, 2020·4 cites·15 claims
- 1192US10428077B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Oct 1, 2019·8 cites·9 claims
- 1291US10266578B2Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·9 cites·30 claims
- 1391US9663466B2Aryl dihydropyridinones and piperidinone MGAT2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 30, 2017·8 cites·7 claims
- 1490US9901572B2Aryl dihydropyridinones and piperidinone MGAT2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Feb 27, 2018·6 cites·21 claims
- 1590US9688695B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jun 27, 2017·11 cites·51 claims
- 1690US9187424B1Aryl dihydropyridinones and piperidinone MGAT2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Nov 17, 2015·10 cites·18 claims
- 1789US10695328B2Aryl dihydropyridinones and piperidinone MGAT2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 30, 2020·2 cites·40 claims
- 1889US6472414B1Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and methodBRISTOL MYERS SQUIBB CO·Filed 1999·Granted Oct 29, 2002·42 cites·12 claims
- 1988US10011594B24-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 3, 2018·4 cites·30 claims
- 2087US7790770B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Sep 7, 2010·10 cites·25 claims
- 2187US7470712B2Amino-benzazoles as P2Y1 receptor inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Dec 30, 2008·10 cites·18 claims
- 2286US10369140B2Aryl dihydropyridinones and piperidinone MGAT2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Aug 6, 2019·3 cites·17 claims
- 2386US9862730B2Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 9, 2018·5 cites·11 claims
- 2486US9518064B2Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 13, 2016·5 cites·18 claims
- 2586US6344450B1Lactam compounds and their use as inhibitors of serine proteases and methodBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Feb 5, 2002·31 cites·29 claims
- 2685US2025002497A1Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2784US7888376B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 15, 2011·8 cites·17 claims
- 2883US7388021B2Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditionsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Jun 17, 2008·8 cites·18 claims
- 2980US12084452B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 10, 2024·0 cites·6 claims
- 3080US10106528B26-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 23, 2018·3 cites·58 claims
- 3179US12097242B2Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 24, 2024·0 cites·26 claims
- 3279US8053450B2Amino-benzazoles as P2Y1 receptor inhibitors with pyridine ring and heterocyclic componentsBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Nov 8, 2011·3 cites·14 claims
- 3378US12097241B2Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 24, 2024·0 cites·17 claims
- 3478US8952180B2Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Feb 10, 2015·2 cites·18 claims
- 3578US7067525B2Compounds useful as modulators of Melanocortin Receptors and pharmaceutical compositions comprising sameBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jun 27, 2006·8 cites·14 claims
- 3678US5883099AInhibitors of microsomal triglyceride transfer protein and methodBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Mar 16, 1999·29 cites·9 claims
- 3777US5543542AMethods of preparing α-phosphonosulfinate squalene synthetase inhibitorsFiled 1995·Granted Aug 6, 1996·20 cites·9 claims
- 3875US11390616B2Apelin receptor agonists and methods of useBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 19, 2022·1 cites·4 claims
- 3975US11364281B2Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jun 21, 2022·0 cites·2 claims
- 4075US8324241B2Triazolo compounds useful as DGAT1 inhibitorsHUANG YANTING·Filed 2009·Granted Dec 4, 2012·5 cites·8 claims
- 4175US6979691B2Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising sameBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 27, 2005·6 cites·18 claims
- 4275US6066650AInhibitors of microsomal triglyceride transfer protein and methodBRISTOL MYERS SQUIBB CO·Filed 1997·Granted May 23, 2000·26 cites·2 claims
- 4375US5470845AMethods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemiaBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Nov 28, 1995·14 cites·14 claims
- 4475US2021161869A1Aryl dihydropyridinones and piperidinone mgat2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 4574US11185570B2Method of treating cardiovascular disease and heart failure with modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 30, 2021·0 cites·20 claims
- 4674US7265145B2Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and methodBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Sep 4, 2007·6 cites·8 claims
- 4772US10966967B2Aryl dihydropyridinones and piperidinone MGAT2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Apr 6, 2021·0 cites·20 claims
- 4871US8304403B2Heterocyclic CETP inhibitorsSALVATI MARK E·Filed 2010·Granted Nov 6, 2012·2 cites·17 claims
- 4970US12168655B2Apelin receptor agonists and methods of useBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Dec 17, 2024·0 cites·14 claims
- 5065US9120794B2Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 1, 2015·0 cites·3 claims
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when R. Michael Lawrence files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →